Evercore ISI Group Maintains Outperform on Medline, Lowers Price Target to $39

Benzinga Newsdesk www.benzinga.com Negative 95.1%

Neg 95.1% Neu 0% Pos 0%

Evercore ISI Group analyst Elizabeth Anderson maintains Medline (NASDAQ:MDLN) with a Outperform and lowers the price target from $48 to $39.